| Sotorasib and adagrasib have been FDA approved for KRAS G12C NSCLC. |
| Divarasib is a potent and selective KRAS G12C inhibitor. |
| Early results show promising efficacy and safety of divarasib. |
| Divarasib may have the potential to change the KRAS G12C treatment landscape. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.